Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Gastrointestinal Neoplasms 3Esophageal Neoplasms 2Stomach Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Pelvic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Appendiceal Neoplasms 1

Interventions

enzalutamide 94Magnetic Resonance Spectroscopy 85Specimen Handling 66Prednisone 63Androgen Antagonists 59Abiraterone Acetate 57apalutamide 55Radiosurgery 52darolutamide 48Radiotherapy 47Leuprolide 46abiraterone 45Docetaxel 42Pluvicto 32Biopsy 31acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 30Radiation 30relugolix 28Surveys and Questionnaires 28gallium 68 PSMA-11 26Standard of Care 26pembrolizumab 25Goserelin 25Triptorelin Pamoate 24Gonadotropin-Releasing Hormone 23bicalutamide 22Brachytherapy 21Carboplatin 20cabazitaxel 19X-Rays 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Pafolacianine × 1 year × Clear all
NCT06434909 2026-06-01

CYTALUXâ„¢for the Intraoperative Imaging of Prostate Cancer

Indiana University

Phase 2 Completed
9 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡